The long-awaited psychedelic-assisted treatment alternative for Post-Traumatic Stress Disorder (PTSD) is moving closer to federal approval.
The Multidisciplinary Association for Psychedelic Studies (MAPS) and its private subsidiary company, MAPS PBC shared the publication of the results from the most advanced clinical trial (Phase 3 study) on MDMA-assisted therapy for the treatment of moderate-to-severe PTSD with solid, confirmatory results on the therapy’s efficacy and safety.
After 18 weeks, 86.5% of participants who received MDMA-assisted therapy experienced a significant reduction in PTSD symptoms, and 71.2% of them no longer met the PTSD diagnostic criteria. This group had remission criteria that more than doubled that of the placebo group (46.2% vs. 21.4%.)
See Also: Can Psychedelics Therapy Be Reimbursed? AMA Releases Details On Coding These Procedures
What Doblin, Industry Leaders And Advocates Are Saying
Rick Doblin, Ph.D., MAPS founder and president, said MDMA-assisted therapy for PTSD “is on track to be considered for approval by the FDA in 2024.”
If approved by the FDA, the DEA would reschedule MDMA making it available for prescription medical use.
The results and expected upcoming approval have been extensively covered by the specialized and mainstream media, including The NY Times and Reuters, further revealing its importance at a global scale.
Co-founder and CEO of a mental healthcare company …
